Category Archives: OTC

Digipath Inc (DIGP: OTCQB) | DigiPath Labs Successfully Completes Proficiency Testing for Cannabis Potency

LAS VEGAS, Oct. 9, 2015 /PRNewswire/ — DigiPath Labs, a subsidiary of DigiPath, Inc. (OTCBB and OTCQB: DIGP), recently successfully completed voluntary proficiency testing of its ability to detect cannabinoids and terpenoids, accurately identifying potency levels of five cannabinoids and 10 terpenoids in unknown samples.  The testing was administered by Absolute Standards, Inc. of Hamden, CT, an independent third-party. “Potency testing is extremely important for patient care,” explains Dr. Cindy Orser, the Chief Science Officer of DigiPath Labs. “The levels of each cannabinoid and terpenoid enable doctors and dispensaries to recommend products and dosages that will help relieve a patient’s symptoms without going overboard. Third party confirmation of our potency testing provides further assurance to our customers as to the quality and reliability of our services.”

DigiPath, Inc., through its subsidiary, DigiPath, Corp., creates and markets innovative and reliable digital pathology solutions that empower private and academic institutions with the ability to create, store, manage, analyze, and correlate data collected through virtual microscopy. DigiPath, Inc. digital pathology portfolio includes PathScope(TM), PathCloud(TM), PathReview(TM), and PathConsult(TM) digital platforms to share and store archive tissue images.

Cannabinoids are chemicals found in the cannabis plant that mimic chemicals naturally found in the human body (endocannabinoids). Cannabinoids from medical marijuana bind with the body’s cannabinoid receptors to rebalance the endocannabinoid system and encourage homeostasis. Terpenoids are compounds found in many plants and are often a component of the smell—lavender, pine, cinnamon, rosemary, and basil have distinct terpene profiles. Many terpenoids have medicinal and antibacterial properties.

In addition to potency testing, DigiPath Labs also performs safety testing for contaminants, including foreign matter, heavy metals, microbials, mycotoxins, pesticides, and solvents.

“Patient safety is our top concern. We helped craft the Nevada testing regulations to be the strictest in the country because we believe that standardization is the only way to ensure that patients know exactly what they’re taking,” explains Todd Denkin, CEO of Digipath Labs. “With this successful test, we have demonstrated that the care we put into setting up the lab and establishing standard operating procedures is paying off.”

For more information about DigiPath Labs, go to

About DigiPath, Inc. (OTCQB: DIGP)
DigiPath, Inc., supports the cannabis industry’s best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the nation. DigiPath’s two business units are DigiPath Labs and TNM News Corp.

For more information, go to

Information about Forward-Looking Statements
This press release contains “forward-looking statements” that include information relating to future events, and future financial and operating performance. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the demand for the Company’s products, the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media Contact: DigiPath Labs, Inc.

Logo –


To view the original version on PR Newswire, visit:

SOURCE DigiPath, Inc.

Article source:

Glassesoff Inc. (GLSO: OTCQB) | GlassesOff’s New Dynamic Game-Like Technology Shows Significant Improvement in Visual Parameters Critical for Sport Performance

NEW YORK, October 9, 2015 /PRNewswire/ —

GlassesOff Inc. (OTCBB: GLSO) announced today the results of a new study among young people that showed significant improvement across multiple visual performance parameters, consistent with an increase in visual processing speed. Visual processing speed is considered critical for superior athletic performance in sports that require swift reaction time.

The new study demonstrated that playing a simple, dynamic mobile game with GlassesOff’s new dynamic technology could result in a significant real-life increase in visual processing speed. In addition, the required daily game-playing duration was successfully decreased to approximately five minutes, a 50% decrease from the older-generation GlassesOff platform technology.

The study included 20 young adults with normal or corrected-to-normal vision in both eyes. All participants completed a total of 40 sessions, and their vision performance was tested before and after the study. Following the use of GlassesOff’s new dynamic game-like technology, participants achieved significant improvement in both far and near visual performance, such as visual acuity, reaction time, stereo acuity and contrast sensitivity. This improvement, together with improvement in temporal masking is consistent with an increase of visual processing speed.

Nimrod Madar, CEO of GlassesOff, said: “When we first set out to develop a new product aiming to improve professional and recreational athletes’ performance, it was clear that we needed to develop a product that doesn’t only demonstrate scientific efficacy, but is also fun to use. We are very pleased with the new generation of our technology, and we continue to focus on the planned launch of our sports application, as well as the anticipated launch of a new GlassesOff™ reading improvement product, which we expect will also use this new platform. With these new launches, we plan on offering our clients, both those seeking to improve in sports and reading, a dynamic and fun game experience that delivers significant value in about five minutes of daily game play.”

GlassesOff will present the findings from the study today, Friday October 9, at the Federation of European Neuroscience Societies (FENS) meeting, in Thessaloniki, Greece at 1:40 PM local time. 

About FENS  

Founded in 1998 at the first Forum of European Neuroscience, the Federation of European Neuroscience Societies (FENS) is the main organization for neuroscience in Europe. FENS currently represents 42 European national and mono-disciplinary neuroscience societies with close to 23,000 member scientists from 32 European countries.

About GlassesOff 

GlassesOff Inc. (OTCBB:GLSO) is public, a neuroscience technology company, utilizing patented technology to develop and commercialize consumer-oriented software applications. The Company is developing and commercializing next generation vision performance applications. GlassesOff has developed a proprietary, patent protected neuroscience technology platform to improve near vision performance through brain exercise, by improving the image processing function in the visual cortex of the brain.

Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “intends,” “estimates,” “suggests,” “has the potential to” and other words and phrases of similar meaning, including statements regarding the results of effectiveness of GLASSESOFF’s applications. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect GLASSESOFF’s business and prospects, including the risks that GLASSESOFF may not succeed in generating any revenues or developing any commercial products, that the products may not achieve the expected results or effectiveness, and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in GLASSESOFF’s filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.


SOURCE GlassesOff Inc.

Article source:

Living Cell Technologies Ltd. (LVCLY: OTCQX International) | Notice of 2015 Annual General Meeting and Proxy Form

Notice of 2015 Annual General Meeting and Proxy Form

Oct 09, 2015

OTC Disclosure News Service

Sydney, NSW, Australia

This release includes additional documents. Select the link(s) below to view.

151009 LCT_Notice_of_AGM_ and Proxy 2015 FINAL VERSION.pdf

Copyright © 2015 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source:

Bunk Beds